Development and establishment of predictive models for the realization of personalized tumor therapy
Granted in 2019 for 3 years.
Here you can get further information.
TITUS - The First Thousand Days of Life
This Else Kröner Research School successfully applied for a second funding period for three more years in 2022.
Here you can find further information.
Gut-brain axis: relevance for inflammation and neurodegeneration
This Else Kröner Research School successfully applied for a second funding period for three more years in 2022.
Here you can find further information.
Immunological Causes and Therapies of Cancer - EXCEL - Excellent Clinician Scientists in Freiburg
Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.
Here you can find further information.
Targeting therapy-induced dynamic alterations within the cancer genome
Granted in 2017 for three years, one-time extension for a further 3 years following a successful review in 2020.
Here you can find further information.
Therapeutic resistance of solid tumours
Granted in 2016 for three years, one-time extension for a further 3 years following a successful review in 2019.
Dissecting the role of bone metastasis-educated neutrophils in inflammation
Neutrophils are the most abundant immune cell type in our blood and first-responders during inflammation and infection. Cancer cells are malignant cells that can move away from the tissue where they are formed, seed and grow in secondary organs. This process is called metastasis and is the leading cause of cancer-associated deaths. Bone metastasis may link to increased risk of infection and inflammation. When cancer cells colonise the bone marrow, site where neutrophils are formed, they alter the maturation of neutrophils.
Microbiome-immune axis in kidney transplant survival and rejection
Kidney transplantation (KT) is the best treatment option for patients with end-stage kidney disease. However, graft availability is limited and graft survival is restricted due to medication-linked toxicity and allograft rejection. Here, we aim to improve the understanding of the mechanisms of acute allograft rejection.
Identification of novel immunotherapeutic targets in AML/MDS with spliceosome mutations using single cell long-read sequencing
Acute myeloid leukemia (AML) is a difficult-to-treat blood malignancy that often relapses despite intensive therapy. Immunotherapies can contribute to preventing relapses. The key to developing novel immunotherapies is the identification of antigens uniquely presented by leukemia cells, enabling their specific elimination by immune cells (T cells). In AML with spliceosome mutations, altered mRNA processing (aberrant splicing) leads to the synthesis and presentation of abnormal antigens (neoepitopes).
Rare diseases of the immune system
Granted in 2013 for three years, one-time extension following a successful review in 2016.